Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.Read more
Advocate for the establishment of public-private partnerships to support chronic disease prevention.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Free trade agreements as they relate to the biopharmaceutical industry.
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 2 moreShow fewer
Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Advocate for the implementation of a federal diabetes and obesity strategy.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Roy Karam · Senior Policy Advisor, Health Canada (HC)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.